William Blair Issues Pessimistic Forecast for APLS Earnings

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) – Research analysts at William Blair decreased their Q2 2025 earnings per share estimates for shares of Apellis Pharmaceuticals in a research note issued on Wednesday, May 7th. William Blair analyst L. Hanbury-Brown now forecasts that the company will earn ($0.52) per share for the quarter, down from their previous estimate of ($0.21). The consensus estimate for Apellis Pharmaceuticals’ current full-year earnings is ($1.70) per share. William Blair also issued estimates for Apellis Pharmaceuticals’ Q3 2025 earnings at ($0.51) EPS, Q4 2025 earnings at ($0.42) EPS, FY2025 earnings at ($2.18) EPS, Q1 2026 earnings at ($0.37) EPS, Q2 2026 earnings at ($0.19) EPS, Q3 2026 earnings at ($0.09) EPS, Q4 2026 earnings at $0.04 EPS and FY2026 earnings at ($0.60) EPS.

Apellis Pharmaceuticals (NASDAQ:APLS) last released its quarterly earnings data on Wednesday, May 7th. The company reported ($0.74) EPS for the quarter, missing the consensus estimate of ($0.36) by ($0.38). Apellis Pharmaceuticals had a negative net margin of 34.97% and a negative return on equity of 103.11%. The company had revenue of $149.90 million during the quarter, compared to analyst estimates of $197.61 million. During the same period in the previous year, the company posted ($0.54) EPS. The company’s quarterly revenue was down 3.2% compared to the same quarter last year.

Other equities research analysts have also recently issued research reports about the company. Bank of America cut Apellis Pharmaceuticals from a “buy” rating to a “neutral” rating and dropped their price target for the company from $41.00 to $23.00 in a research note on Friday. Wells Fargo & Company reduced their target price on Apellis Pharmaceuticals from $30.00 to $26.00 and set an “equal weight” rating on the stock in a report on Thursday. Cantor Fitzgerald initiated coverage on Apellis Pharmaceuticals in a research note on Tuesday, April 29th. They issued an “overweight” rating and a $44.00 price objective on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $57.00 price objective on shares of Apellis Pharmaceuticals in a research note on Monday, March 3rd. Finally, Royal Bank of Canada cut their price target on Apellis Pharmaceuticals from $21.00 to $18.00 and set a “sector perform” rating on the stock in a research note on Thursday. Nine investment analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $41.37.

Apellis Pharmaceuticals Stock Down 2.9%

APLS opened at $17.30 on Monday. Apellis Pharmaceuticals has a 1-year low of $16.65 and a 1-year high of $43.99. The stock’s fifty day simple moving average is $21.15 and its 200 day simple moving average is $27.05. The company has a current ratio of 4.36, a quick ratio of 3.73 and a debt-to-equity ratio of 1.91. The stock has a market cap of $2.17 billion, a PE ratio of -8.52 and a beta of 0.73.

Institutional Investors Weigh In On Apellis Pharmaceuticals

Hedge funds and other institutional investors have recently modified their holdings of the company. Barclays PLC grew its holdings in Apellis Pharmaceuticals by 18.0% during the third quarter. Barclays PLC now owns 255,897 shares of the company’s stock worth $7,381,000 after buying an additional 39,019 shares in the last quarter. Eastern Bank lifted its holdings in Apellis Pharmaceuticals by 87.0% during the 4th quarter. Eastern Bank now owns 21,500 shares of the company’s stock worth $686,000 after purchasing an additional 10,000 shares in the last quarter. Hennion & Walsh Asset Management Inc. lifted its holdings in Apellis Pharmaceuticals by 135.6% during the 4th quarter. Hennion & Walsh Asset Management Inc. now owns 29,740 shares of the company’s stock worth $949,000 after purchasing an additional 17,115 shares in the last quarter. Merit Financial Group LLC purchased a new stake in Apellis Pharmaceuticals during the 4th quarter worth about $254,000. Finally, KBC Group NV increased its stake in Apellis Pharmaceuticals by 3,862.3% in the 4th quarter. KBC Group NV now owns 104,287 shares of the company’s stock worth $3,328,000 after acquiring an additional 101,655 shares during the last quarter. Institutional investors own 96.29% of the company’s stock.

Insiders Place Their Bets

In other news, General Counsel David O. Watson sold 5,569 shares of the business’s stock in a transaction that occurred on Wednesday, March 5th. The stock was sold at an average price of $25.10, for a total transaction of $139,781.90. Following the completion of the sale, the general counsel now owns 138,730 shares in the company, valued at $3,482,123. The trade was a 3.86% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Over the last three months, insiders sold 6,115 shares of company stock worth $154,684. 6.50% of the stock is owned by corporate insiders.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).